The first academic article using the term “financial toxicity” was published in 2013, 1 which catalyzed the growth of an emerging field of research and quality improvement efforts focused on addressing patient affordability concerns. Although previous research had begun to describe the financial burden experienced by patients with cancer and the exorbitant costs of cancer care, the seminal article from Zafar et al and the subsequent editorials from experts we now recognize as leaders in this field